The CLARITY study: efficacy outcomes among patients who received disease-modifying therapies prior to treatment with cladribine tablets

被引：0
|
作者：
Vermersch, P. [1 ]
Rammohan, K. [2 ]
Damian, D. [3 ]
Jack, D. [4 ]
Harty, G. [3 ]
Wong, S. L. [3 ]
机构：
[1] Univ Lille, INSERM, U995, CHU Lille,FHU Imminent, Lille, France
[2] Univ Miami, Sch Med, Dept Neurol, MS Res Ctr, Miami, FL USA
[3] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[4] Merck Healthcare KGaA, Darmstadt, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P624
引用
收藏
页码：301 / 302
页数：2
相关论文
共 50 条
  • [1] The CLARITY Study: Efficacy Outcomes Among Patients Who Received Disease-modifying Drugs Prior To Treatment With Cladribine Tablets
    Vermersch, P.
    Rammohan, K.
    Damian, D.
    Jack, D.
    Harty, G.
    Wong, S. L.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 49 - 49
  • [2] Cladribine tablets in patients who had failed prior treatment with injectable disease-modifying drugs for relapsing-remitting multiple sclerosis: evaluation of treatment effect in the CLARITY study
    Cook, S.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. Soelberg
    Vermersch, P.
    Scarramozza, M.
    Chang, P.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2011, 258 : 260 - 260
  • [3] Evaluation of the Treatment Effect of Cladribine Tablets in the Cohort of Patients Who Had Failed Prior Treatment with Injectable Disease-Modifying Drugs: The CLARITY Relapsing-Remitting Multiple Sclerosis Study
    Cook, Stuart
    Comi, Giancarlo
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Scaramozza, Matthew
    Chang, Peter
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A322 - A323
  • [4] Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis: post hoc analysis of subgroups with and without prior disease-modifying drug treatment
    Vermersch, Patrick
    Galazka, Andrew
    Dangond, Fernando
    Damian, Doris
    Wong, Schiffon L.
    Jack, Dominic
    Harty, Gerard
    CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (03) : 459 - 464
  • [5] Disease-modifying treatment patterns of patients with multiple sclerosis and newly treated with cladribine tablets or fingolimod: an interim analysis of the CLARION study
    Butzkueven, H.
    Hillert, J.
    Sonajalg, J.
    Soilu-Hanninen, M.
    Aydemir, A.
    Ziemssen, T.
    Kuhle, J.
    Magyari, M.
    Wergeland, S.
    Bezemer, I.
    Sabido, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 622 - 623
  • [6] The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies
    Freedman, Mark S.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Olsson, Tomas P.
    Miller, Aaron E.
    Thangavelu, Karthinathan
    Benamor, Myriam
    Truffinet, Philippe
    O'Connor, Paul W.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (04) : 535 - 539
  • [7] Efficacy Outcomes In Cladribine Tablets-treated Patients In CLARITY Were Similar Between Patients Who Did Vs. Did Not Enter CLARITY Extension
    Comi, G.
    Soelberg-Sorensen, P.
    Rammohan, K.
    Giovannoni, G.
    Damian, D.
    Jack, D.
    Dangond, F.
    Galazka, A.
    Jones, D. L.
    Vermersch, P.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 43 - 43
  • [8] Efficacy outcomes in cladribine tablets-treated patients in CLARITY were similar between patients who did vs. did not enter CLARITY extension
    Comi, G.
    Sorensen, P. Soelberg
    Rammohan, K.
    Giovannoni, G.
    Damian, D.
    Jack, D.
    Dangond, F.
    Galazka, A.
    Jones, D. L.
    Vermersch, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 1136 - 1136
  • [9] Impact of Treatment Adherence on Clinical and Economic Outcomes among Multiple Sclerosis Patients Receiving Disease-Modifying Therapies
    Tan, Hiangkiat
    Cai, Qian
    Agarwal, Sonalee S.
    Kamat, Siddhesh A.
    NEUROLOGY, 2010, 74 (09) : A365 - A365
  • [10] Treatment discontinuation and restart among patients with multiple sclerosis using disease-modifying therapies
    Fox, R.
    Mehta, R.
    Pham, T.
    Park, J.
    Wilson, K.
    Bonafede, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 558 - 559
12345